CD86 and breast cancer: To our surprise, by flow cytometry analysis, the M2 TAMs (CD206+F4/80+) were increased by nearly two-fold in EPZ-6438-treated BC-PDX6305 tumor tissues (Fig. 1B), meanwhile the number of M1 TAMs (CD86+F4/80+) decreased a little bit.